Key strengths

Leader in allergy and epilepsy

• World leader in allergy with Zyrtec® and Xyzal®
• US and European leader in epilepsy with Keppra®

A world leader in antibody research

• SLAM technology to rapidly isolate functionally active antibodies.

12 large and small molecules in clinical development

• 5 large, antibody-based molecules
• 7 small, chemically-derived molecules
• Broad range of molecules in late research and pre-clinical development.

Over 30 major R&D and commercial partnerships

• Includes Amgen, Biogen IDEC and Pfizer.

A global R&D, marketing and sales platform

• Operations in more than 40 countries worldwide
• 10 R&D sites across Europe, Japan and the United States.